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Abstract
Background: A recently published genome-wide association study (GWAS) of late-onset Alzheimer’s disease
(LOAD) revealed genome-wide significant association of variants in or near MS4A4A, CD2AP, EPHA1 and CD33. Meta-
analyses of this and a previously published GWAS revealed significant association at ABCA7 and MS4A, independent
evidence for association of CD2AP, CD33 and EPHA1 and an opposing yet significant association of a variant near
ARID5B. In this study, we genotyped five variants (in or near CD2AP, EPHA1, ARID5B, and CD33) in a large (2,634
LOAD, 4,201 controls), independent dataset comprising six case-control series from the USA and Europe. We
performed meta-analyses of the association of these variants with LOAD and tested for association using logistic
regression adjusted by age-at-diagnosis, gender, and APOE ε4 dosage.
Results: We found no significant evidence of series heterogeneity. Associations with LOAD were successfully
replicated for EPHA1 (rs11767557; OR = 0.87, p = 5 × 10
-4) and CD33 (rs3865444; OR = 0.92, p = 0.049), with odds
ratios comparable to those previously reported. Although the two ARID5B variants (rs2588969 and rs494288)
showed significant association with LOAD in meta-analysis of our dataset (p = 0.046 and 0.008, respectively), the
associations did not survive adjustment for covariates (p = 0.30 and 0.11, respectively). We had insufficient
evidence in our data to support the association of the CD2AP variant (rs9349407, p = 0.56).
Conclusions: Our data overwhelmingly support the association of EPHA1 and CD33 variants with LOAD risk:
addition of our data to the results previously reported (total n > 42,000) increased the strength of evidence for
these variants, providing impressive p-values of 2.1 × 10
-15 (EPHA1) and 1.8 × 10
-13 (CD33).
Background
Following the identification of the APOE ε4a l l e l ea sa
risk factor for late-onset Alzheimer’s disease (LOAD) in
1993 [1], consistent replication of subsequently identi-
fied candidates was not achieved until 2009, when two
genome-wide association studies (GWAS) [2,3] identi-
fied associations of variants in or near CLU, PICALM ,
and CR1 with LOAD, which were consistently replicated
in multiple large, independent case-control studies
[4-17]. Subsequently, a variant near BIN1 was reported
[4] to achieve genome-wide significant association in a
later GWAS published in 2010 that also replicated well
in follow-up studies [14-19]. These results demonstrate
the utility of the hypothesis-free GWAS approach for
identifying loci that associate with LOAD and the neces-
sity of pooling samples and data from multiple centers
to obtain resources with sufficient statistical power
(GWAS typically > 14,000, follow-up typically total >
28,000) to detect the modest ORs (e.g. 0.8/1.2) asso-
ciated with these variants in GWAS and follow-up
studies.
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worth et al. [20] and Naj et al. [17] performed meta-
analysis of two large GWAS datasets (n > 75,000).
Besides APOE, CLU, PICALM,a n dCR1,t h em e t a - a n a -
lyses revealed association at ABCA7 (p = 5 × 10
-21),
MS4A6A ( p=1 . 2×1 0
-16), MS4A4E ( p=1 . 1×1 0
-10),
EPHA1 ( p=6×1 0
-10), CD2AP ( p=8 . 6×1 0
-9)a n d
CD33 (p = 1.6 × 10
-9). In addition, the two datasets
revealed opposing association (Naj et al. OR = 0.93, p =
0.001; Hollingworth et al. OR = 1.06, p = 0.03) of the
variant near ARID5B (rs2588969) with LOAD, suggest-
ing potential heterogeneity at this locus. In this study,
we genotyped the variants identified at the CD2AP,
EPHA1,a n dCD33 loci in our independent case-control
dataset comprising six case-control series (n = 6,835).
To assess the opposing associations at the ARID5B
locus, we also genotyped the two ARID5B variants
included in the Hollingworth et al. study. Genotypes
from our follow-up case-control series (Mayo 2) for var-
iants in ABCA7, MS4A6A and MA4A4E were included
in Stage 3 of the Hollingworth et al.s t u d y ,s ow eh a v e
not included these three variants in this study. We have
performed meta-analyses of five variants (at CD2AP,
EPHA1, ARID5B and CD33 loci) in our six case-control
series, which showed no significant series heterogeneity.
Furthermore, we have performed logistic regression ana-
lysis of our pooled series adjusting for covariates. Finally,
we have used a Fisher’s combined test to evaluate the
significance of the association of these five variants in
our data combined with the data in the Hollingworth et
al. and Naj et al. studies.
Results
We genotyped five variants (CD2AP; rs9349407, EPHA1;
rs11767557, ARID5B; rs2588969 and rs4948288, CD33;
rs3865444) in our independent follow-up case-control
series (Mayo2) from three North American and three
European Caucasian series. Detailed information about
these samples is shown in Table 1 and genotype counts
are shown in Table 2. Samples used in this study do not
overlap with those included in the Naj et al. study and
have not been included in any of the published LOAD
GWAS. The Mayo2 dataset included in the Holling-
worth et al. publication only included genotypes for
ABCA7, MS4A6A and MA4A4E.
Meta-analyses of allelic association in the six Mayo2
series performed using a DerSimonian-Laird random
effects model (Figure 1) revealed a significant pooled
OR for the EPHA1 variant (Figure 1b; OR = 0.88, p =
0.008) comparable to that previously published by Naj et
al. (OR = 0.87) and by Hollingworth et al.( O R=0 . 9 0 ) .
As shown in Figure 1c and 1d, we also observed signifi-
cant association for both ARID5B variants (rs2588969,
OR = 1.08, p = 0.046; rs4948288, OR = 1.11, p = 0.008)
with ORs comparable to those reported by Hollingworth
et al. (OR = 1.06 and 1.07, respectively) and in the
opposing direction to those reported by Naj et al.f o r
rs2588969 (Stage 1+2 OR = 0.93, p = 7.7 × 10
-4). As
s h o w ni nF i g u r e1 aa n d1 e ,w ed i dn o to b s e r v es i g n i f i -
cant association for CD2AP (OR = 0.98, p = 0.76) or
CD33 (OR = 0.96, p = 0.32) in our meta-analyses. Bre-
slow-Day tests provided no significant evidence that the
ORs for any of these variants were heterogeneous
among our series (all p > 0.25), as shown in Figure 1.
The variant with the most heterogeneity was CD2AP
(rs9349407) where the estimated percentage of variation
due to heterogeneity across studies (I
2) was 25.1% (95%
CI 0%-70%) suggesting the presence of some heteroge-
neity for that variant.
To adjust for important covariates, we included age-
at-diagnosis/entry, sex and APOE ε 4 dosage in logistic
regression analyses of all five variants in each of the six
Mayo2 series; in our analysis of all Mayo2 series com-
bined, series was included as an additional covariate.
Table 3 shows the results for the six Mayo2 series com-
bined (Mayo follow-up) as well as for each of the six
individual Mayo2 series. For the purpose of comparison,
we have also included in Table 3 the published GWAS
Table 1 Details of the Mayo2 samples used in this study and genotype counts
Number of samples Mean Age (SD) % Female % ε4+
Series AD CON Total AD CON AD CON AD CON
Jacksonville 507 967 1,474 80.0 (6.7) 81.7 (7.6) 61.9 56.3 60.2 21.8
Rochester 317 1,638 1,955 85.8 (4.5) 80.3 (5.2) 62.1 54.6 42.3 22.4
Autopsy 312 102 414 87.4 (4.8) 86.0 (4.3) 67.6 52.0 61.2 14.7
Norway 346 555 901 80.2 (7.3) 75.3 (6.8) 69.9 59.8 63.0 24.1
Poland 483 188 671 76.7 (4.8) 73.0 (5.9) 66.3 76.6 56.4 19.0
ARUK 669 751 1,420 75.6 (8.2) 76.2 (7.3) 55.6 49.9 58.0 24.4
The number of LOAD patients (AD) and controls (CON), mean age-at-diagnosis, percentage that are female and percentage that possess at least one copy of the
APOE ε 4 allele are given for each individual series. Mean age is given as age at diagnosis/entry with the standard deviation (SD) from the mean in parentheses.
None of the samples comprising the Jacksonville, Rochester and autopsy-confirmed Mayo Clinic or ARUK series (comprising Bristol, Leeds, Manchester,
Nottingham, Oxford and Southampton), which were included in this follow-up study overlap with those used in the Naj et al. study and have not been included
in any of the published LOAD GWAS. The Mayo2 dataset included in the Hollingworth et al. publication only included genotypes for ABCA7, MS4A6A and
MA4A4E.
Carrasquillo et al. Molecular Neurodegeneration 2011, 6:54
http://www.molecularneurodegeneration.com/content/6/1/54
Page 2 of 9results for the same variants. Adjustment for covariates
revealed comparable ORs to those obtained in the meta-
analyses, with improved p-values for the EPHA1 (OR =
0 . 8 7 ,p=5×1 0
-4), CD33 (OR = 0.92, p = 0.049) and
CD2AP (OR = 0.97, p = 0.56) loci. However, the asso-
ciations of the ARID5B variants were no longer signifi-
cant following adjustment for covariates (rs2588969: OR
= 1.05, p = 0.30, rs4948288: OR = 1.07, p = 0.11) sug-
gesting that these associations may be dependent upon
the series, age-at-diagnosis/entry, sex and/or APOE ε 4
dosage of the individual.
In order to estimate the overall association of these
five variants in our data combined with the previously
published associations, we used Fisher’s method to com-
bine the p-values for all associations (Table 3; Mayo2/
ADGC/Hollingworth). We found that adding our data
to those previously reported, increased the strength of
evidence for all variants as LOAD risk modifiers
(CD2AP:p=6 . 5×1 0
-11, EPHA1:p=2 . 1×1 0
-15,
ARID5B rs2588969: p = 2.3 × 10
-9, ARID5B rs4948288:
p = 4.0 × 10
-4, CD33: p = 1.8 × 10
-13).
Discussion
We report here successful replication of the association
of two variants with LOAD in a large (n = 6,835), inde-
pendent case-control study; rs11767557, which is
located 3 kb upstream of EPHA1 ( p=5×1 0
-4)a n d
rs3865444, which is located 373 bp upstream of CD33
(p = 0.049). The ORs we observed in our meta-analyses
(EPHA1 =0 . 8 8 ,CD33 = 0.96) were comparable to those
reported by both Naj et al.( EPHA1 = 0.87, CD33 =
0.89) and by Hollingworth et al.( EPHA1 =0 . 9 0 ,CD33
= 0.89) such that the estimated p-values for association
of these variants in all data (n > 42,000) were an
impressive 2.1 × 10
-15 for EPHA1 and 1.8 × 10
-13 for
CD33.
Although our meta-analyses showed successful repli-
cation of the association of the ARID5B variants
rs2588969 (OR = 1.08, p = 0.046) and rs4948288 (OR =
1.11, p = 0.008) with a direction of association consis-
tent with that reported by Hollingworth et al.( O R=
1.06 and 1.07, respectively), the associations did not sur-
vive adjustment for age-at-diagnosis/entry, sex and
APOE ε 4 status (p = 0.30 and 0.11, respectively). This
covariate-dependent association could explain the
opposing association reported by Naj et al.i nt h e i rd i s -
covery (OR = 0.88) and replication (OR = 1.05) datasets
for rs2588969; the only ARID5B variant they tested.
Therefore, while estimation of the p-values for associa-
tion of the ARID5B variants in all datasets combined
were highly significant (rs2588969; p = 2.3 × 10
-9 and
rs4948288; p = 4.0 × 10
-4), interpretation of these asso-
ciations should be treated with caution and should take
into account the age-at-diagnosis/entry, sex and APOE ε
4 dosage of the populations. Finally, although the esti-
mated p-value for association of rs9349407 (located in
intron 1of CD2AP) in all datasets was 6.5 × 10
-11,t h e r e
was no evidence for association of this variant in our
dataset alone (OR = 0.97, p = 0.56).
Our Mayo2 collection of case-control series studies
provided a total of 2,634 LOAD and 4,201 controls.
Combining across studies to perform global tests of sig-
nificance for additive genotypic trend tests gave us 80%
p o w e rt od e t e c tO R sr a n g i n gf r o m1 . 1 7( o r0 . 8 5 5 )f o r
variants with a minor allele frequency (MAF) of 0.2 to
1.13 (or 0.883) for variants with a MAF of 0.45 in con-
trols. The study provided approximately 60% power to
detect the OR of 1.11 that we report for CD2AP (MAF
= 0.27).
Case-control studies such as this are not designed to
ascertain whether the variants with reported associa-
tion with LOAD risk are the functional variant but
Table 2 Genotype counts for each of the six Mayo2 series
CD2AP (rs9349407) EPHA1 (rs11767557) ARID5B (rs2588969) ARID5B (rs4948288) CD33 (rs3865444)
GG/GC/CC GG/GC/CC TT/TC/CC TT/TC/CC CC/CA/AA CC/CA/AA GG/GA/AA GG/GA/AA CC/CA/AA CC/CA/AA
Series AD CON AD CON AD CON AD CON AD CON
Jacksonville 254/197/41 497/369/56 339/143/
19
612/301/44 188/226/81 379/400/149 164/233/99 351/426/148 251/200/41 446/386/88
Rochester 170/126/17 843/640/117 198/102/9 985/518/69 100/159/48 623/755/226 92/172/50 581/748/250 148/134/30 715/692/170
Autopsy 156/110/19 49/44/7 205/97/5 61/28/10 118/148/42 50/38/14 115/142/43 38/43/17 141/125/32 42/44/11
Norway 177/131/16 273/205/41 212/113/
13
337/185/26 129/165/44 215/250/78 115/156/53 184/268/88 153/139/35 248/236/57
Poland 235/193/40 100/70/11 297/140/
20
108/52/9 153/243/77 65/91/29 160/222/84 62/96/26 224/204/39 96/83/8
ARUK 341/243/55 363/317/53 386/191/
20
439/234/37 236/313/
101
271/367/102 208/326/
122
259/351/122 289/286/67 329/307/94
Total 1333/1000/
188
2125/1645/
285
1637/786/
86
2542/1318/
195
924/1254/
393
1603/1901/
598
854/1251/
451
1475/1932/
651
1206/1088/
244
1876/1748/
428
The genotype counts (major allele homozygotes/heterozygotes/minor allele homozygotes) for CD2AP (rs9349407), EPHA1 (rs11767557), ARID5B (rs2588969 and
rs4948288) and CD33 (rs3865444) variants are given for each individual series.
Carrasquillo et al. Molecular Neurodegeneration 2011, 6:54
http://www.molecularneurodegeneration.com/content/6/1/54
Page 3 of 9they can identify a linkage disequilibrium (LD) block
within which a truly functional variant may reside. Our
results indicate that the EPHA1 and CD33 variants
represent excellent candidates for targeted deep
sequencing or high density genotyping in order to
define the locus further, followed by subsequent func-
tional studies of nearby genes to elucidate the mechan-
ism behind these associations. With the exception of
rs9349407, which lies within intron 1of CD2AP,a l lo f
these variants lie within intergenic regions but for ease
of the reader, we have thus far only referred to the
nearest gene for each variant. This by no means sig-
nifies that these variants (or the functional variants in
LD with them) are assumed to affect the expression or
function of the nearest gene but may affect other
nearby genes. Until it is known which gene underlies
these associations, all nearby genes should be included
in follow-up functional investigation (all genes that
r e s i d ew i t h i n1 0 0k bo ft h e se variants are listed in
Additional file 1, Table S1).
Conclusions
Taken along with our previous publications [5,18,20,21],
we have now performed follow-up association studies of
25 of the top GWAS-identified candidate LOAD genes
and successfully replicated the association of eleven var-
iants (in or near ABCA7, BIN1, CD33, CLU, CR1,
EPHA1, GAB2, LOC651924, MS4A6A/4E and PICALM),
eight of which are currently ranked in the top ten (after
APOE) on AlzGene. This recent success in replicating
genetic association highlights the utility of multiple,
large case-control follow-up studies to confirm the
novel associations reported by large GWAS, thus con-
firming them as good candidate genes for functional fol-
low-up studies.
Methods
Ethics statement
Approval was obtained from the ethics committee or
institutional review board of each institution responsible
for the ascertainment and collection of samples. Written
informed consent was obtained for all individuals that
participated in this study.
Case-control subjects
The Mayo2 case-control series consisted of Caucasian
subjects from the United States ascertained at the
Mayo Clinic Jacksonville, Mayo Clinic Rochester, or
through the Mayo Clinic Brain Bank. Additional Cau-
casian subjects from Europe were obtained from Nor-
way [22], Poland [23], and from six research institutes
in the United Kingdom that are part of the Alzheimer’s
Research UK (ARUK) Network. Although the ARUK
s a m p l e su s e di nt h i sf o l l o w - u pd on o to v e r l a pw i t h
Figure 1 Forest plots for meta-analysis of CD2AP, EPHA1,
ARID5B, and CD33 variants in our six Mayo2 case-control
series. ORs (boxes) and 95% CI (whiskers) are plotted for each
population and shown on the right of each plot. Combined OR is
the overall OR calculated by the meta-analysis using a random
effects model. P-values are provided for the combined ORs and
Breslow-Day tests of heterogeneity. I2 gives an estimate of between
studies variance.
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Page 4 of 9Table 3 Association of CD2AP, EPHA1, ARID5B, and CD33 variants with LOAD in the initial studies (ADGC and GERAD+)
and Mayo2 follow-up series
N
a MAF
b Association test
Study Cases Controls Cases Controls OR (95% CI) p-value
CD2AP-rs9349407-C (minor) allele
ADGC Discovery (Stage 1) 8,309 7,366 1.14 (1.08-1.21) 1.2 × 10
-6
ADGC Replication (Stage 2) 3,531 3,565 1.07 (0.98-1.17) 0.12
ADGC combined analysis (Stages 1+2) 11,840 10,931 1.12 (1.07-1.18) 1.0 × 10
-6
Hollingworth et al. (GERAD + Consortia) 6,283 7,165 1.11 (1.04-1.18) 8×1 0
-4
Mayo2
c 2,521 4,055 0.27 0.27 0.97 (0.89-1.07) 0.56
Jacksonville 492 922 0.28 0.26 1.10 (0.91-1.33) 0.34
Rochester 313 1,600 0.26 0.27 0.88 (0.70-1.09) 0.24
Autopsy 285 100 0.26 0.29 0.98 (0.65-1.47) 0.92
Norway 324 519 0.25 0.28 0.81 (0.62-1.06) 0.13
Poland 468 181 0.29 0.25 1.04 (0.77-1.42) 0.79
ARUK 639 733 0.28 0.29 0.97 (0.81-1.16) 0.72
ADGC/Hollingworth
d 18,123 18,096 1.2 × 10
-10
Mayo2/ADGC/Hollingworth
e 20,644 22,151 6.5 × 10
-11
EPHA1-rs11767557-C (minor) allele
ADGC Discovery (Stage 1) 8,309 7,366 0.85 (0.80-0.90) 7.3 × 10
-8
ADGC Replication (Stage 2) 3,531 3,565 0.94 (0.86-1.03) 0.17
ADGC combined analysis (Stages 1+2) 11,840 10,931 0.87 (0.83-0.92) 2.4 × 10
-7
Hollingworth et al (GERAD + Consortia) 6,283 12,935 0.90 (0.85-0.95) 3.4 × 10
-4
Mayo2
c 2,509 4,055 0.19 0.21 0.87 (0.78-0.96) 5.5 × 10
-4
Jacksonville 501 957 0.18 0.20 0.86 (0.70-1.06) 0.17
Rochester 309 1,572 0.19 0.21 0.89 (0.69-1.13) 0.33
Autopsy 307 99 0.17 0.24 0.66 (0.43-1.02) 0.06
Norway 338 548 0.21 0.22 0.94 (0.71-1.24) 0.67
Poland 457 169 0.20 0.21 0.93 (0.66-1.31) 0.67
ARUK 597 710 0.19 0.22 0.85 (0.69-1.04) 0.12
ADGC/Hollingworth
d 18,123 18,096 4.2 × 10
-12
Mayo2/ADGC/Hollingworth
e 20,632 27,921 2.1 × 10
-15
ARID5B-rs2588969-A (minor) allele
ADGC Discovery (Stage 1) 8,309 7,366 0.88 (0.84-0.93) 1.1 × 10
-6
ADGC Replication (Stage 2) 3,531 3,565 1.05 (0.97-1.13) 0.23
ADGC combined analysis (Stages 1+2) 11,840 10,931 0.93 (0.89-0.97) 0.001
Hollingworth et al (GERAD + Consortia) 6,283 7,165 1.06 (1.01-1.13) 0.03
Mayo2
c 2,571 4,102 0.40 0.38 1.05 (0.96-1.14) 0.30
Jacksonville 495 928 0.39 0.38 1.04 (0.88-1.23) 0.63
Rochester 307 1,604 0.42 0.38 1.12 (0.92-1.37) 0.26
Autopsy 308 102 0.38 0.32 1.24 (0.86-1.79) 0.24
Norway 338 543 0.37 0.37 1.05 (0.83-1.33) 0.69
Poland 473 185 0.42 0.40 0.91 (0.68-1.20) 0.49
ARUK 650 740 0.40 0.39 1.05 (0.88-1.24) 0.61
ADGC/Hollingworth
d 18,123 18,096 7.6 × 10
-9
Mayo2/ADGC/Hollingworth
e 20,694 22,198 2.3 × 10
-9
ARID5B-rs4948288-A (minor) allele
ADGC Discovery (Stage 1) 8,309 7,366
ADGC Replication (Stage 2) 3,531 3,565
ADGC combined analysis (Stages 1+2) 11,840 10,931
Hollingworth et al (GERAD + Consortia) 6,992 13,472 1.07 (1.03-1.15) 3.6 × 10
-3
Mayo2
c 2,556 4,058 0.42 0.40 1.07 (0.99-1.16) 0.11
Jacksonville 496 925 0.43 0.39 1.13 (0.96-1.34) 0.14
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Hollingworth et al., the same subject/sample ascertain-
ment methodology was followed. The ARUK series
included here are from Bristol, Leeds, Manchester,
Nottingham, Oxford and Southampton. Since the Man-
chester cohort only consisted of LOAD cases, the
Manchester cases were combined with subjects in the
Nottingham series.
Genotyping
All genotyping was performed at the Mayo Clinic in
Jacksonville using TaqMan
® SNP Genotyping Assays in
an ABI PRISM
® 7900HT Sequence Detection System
with 384-Well Block Module from Applied Biosystems,
California, USA. The genotype data was analyzed using
the SDS software version 2.2.3 (Applied Biosystems,
California, USA).
Statistical Analyses
Meta-analysis of allelic association and Breslow-Day
tests were performed using StatsDirect v2.5.8 software.
Meta-analyses were performed using the results from
each individual case-control series. Summary ORs and
95% CI were calculated using the DerSimonian and
Laird (1986) random-effects model [24]. Breslow-Day
tests were used to test for heterogeneity between
populations. PLINK software [25] (http://pngu.mgh.
harvard.edu/purcell/plink/) was used to perform logis-
tic regression analysis under an additive model adjust-
ing for age-at-diagnosis, sex and APOE ε 4d o s ea s
covariates. In our analysis of all series combined, series
was included as an additional covariate. Since genotype
counts were not reported for series included in the Naj
et al.o rH o l l i n g w o r t het al.s t u d i e s ,w ee m p l o y e da
Fisher combined test to combine p-values across series.
Power calculations, based on a Mantel-Haenszel chi-
square test that pooled across six different study
groups, were obtained to estimate the detectable odds
ratios for an ordinal effect using a range of minor
allele frequencies spanning those expected from the
candidate variants.
Table 3 Association of CD2AP, EPHA1, ARID5B, and CD33 variants with LOAD in the initial studies (ADGC and GERAD+)
and Mayo2 follow-up series (Continued)
Rochester 314 1,579 0.43 0.40 1.08 (0.89-1.32) 0.43
Autopsy 300 98 0.38 0.39 0.91 (0.63-1.32) 0.61
Norway 324 540 0.40 0.41 1.06 (0.83-1.34) 0.64
Poland 466 184 0.42 0.40 0.90 (0.68-1.20) 0.48
ARUK 656 732 0.43 0.41 1.13 (0.96-1.33) 0.14
Mayo2/ADGC/Hollingworth
e 9,548 17,530 4.0 × 10
-4
CD33 -rs3865444-A (minor) allele
ADGC Discovery (Stage 1) 8,309 7,366 0.88 (0.84-0.93) 8.2 × 10
-7
ADGC Replication (Stage 2) 3,531 3,565 0.91 (0.85-0.99) 0.02
ADGC combined analysis (Stages 1+2) 11,840 10,931 0.89 (0.86-0.93) 1.1 × 10
-7
Hollingworth et al (GERAD + Consortia) 6,283 7,165 0.89 (0.84-0.95) 2.2 × 10
-4
Mayo2
c 2538 4052 0.31 0.32 0.92 (0.84-1.00) 4.9 × 10
-2
Jacksonville 492 920 0.29 0.31 0.82 (0.68-0.98) 0.03
Rochester 312 1,577 0.31 0.33 0.88 (0.72-1.08) 0.23
Autopsy 298 97 0.32 0.34 0.84 (0.57-1.24) 0.39
Norway 327 541 0.32 0.32 0.89 (0.70-1.14) 0.37
Poland 467 187 0.30 0.26 1.00 (0.72-1.37) 0.99
ARUK 642 730 0.33 0.34 0.98 (0.83-1.17) 0.85
ADGC/Hollingworth
d 18,123 18,096 3.6 × 10
-12
Mayo2/ADGC/Hollingworth
e 20,661 22,148 1.8 × 10
-13
Abbreviations: MAF, minor allele frequency; OR, odds ratio for the minor allele; 95% CI, 95% confidence interval
aThe numbers shown for the series in the Naj et al. and Hollingworth et al. studies refer to the complete set analyzed. The numbers for the Mayo follow-up data
refer to the number of samples successfully genotyped.
bMAFs were not reported for LOAD and control groups in the Naj et al. or Hollingworth et al. studies.
cThe results shown here for the Mayo2 follow-up dataset combined and for the subseries were obtained using logistic regression adjusted for age, sex and APOE
ε 4 dosage. The Mayo2 follow-up dataset reported here is independent of that which was incorporated in the GWAS reported by Hollingworth et al. The results
for each of the Mayo follow-up subseries (Jacksonville, Rochester, Autopsy-confirmed, Norway, Poland and ARUK) are listed immediately below the results for the
Mayo2 follow-up dataset combined.
dIndicates Fisher’s combined p-value for each individual GWAS in the Naj et al. study (Combined) and the Hollingworth et al. study.
eIndicates Fisher’s combined p-value for each individual GWAS in the Naj et al. study (Combined), the Hollingworth et al. study and Mayo2 independent follow-
up series.
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Additional file 1: Table S1. Genes located within 100 kb of the five
variants tested in this study. Chr, chromosome. Base pair positions (bp)
are relative to the NCBI Human Genome build 36.1. The position of the
variant relative to the gene is given as 5’ (upstream from the gene’s
transcription start site) or 3’ (downstream from the gene’s last exon).
Distance indicates the number of base pairs from the variant position to
the gene’s nearest exon.
Abbreviations
ABCA7: ATP-binding cassette, sub-family A (ABC1), member 7; AD:
Alzheimer’s disease; ADGC: Alzheimer’s disease Genetic Consortium; APOE:
apolipoprotein E; ARID5B: AT rich interactive domain 5B (MRF1-like); ARUK:
Alzheimer’s Research United Kingdom; BIN1: bridging integrator 1; Bp: base
pair; CD2AP: CD2-associated protein; CD33: CD33 molecule; CI: confidence
interval; CLU: clusterin; CR1: complement component (3 b/4 b) receptor 1
(Knops blood group); EPHA1: EPH receptor A1; GAB2: GRB2-associated
binding protein 2; GERAD: Genetic and Environmental Risk in Alzheimer’s
Disease Consortium; GWAS: genome-wide association study; kb: kilobases;
LD: linkage disequibrium; LOAD: late-onset Alzheimer’s disease; MAF: minor
allele frequency; MS4A4A: membrane-spanning 4-domains, subfamily A,
member 4; OR: odds ratio; PICALM: phosphatidylinositol binding clathrin
assembly protein; SD: standard deviation.
Acknowledgements and Funding
We thank contributors, including the Alzheimer’s disease centers who
collected samples used in this study, as well as subjects and their families,
whose help and participation made this work possible. We thank the
members of the Alzheimer’s Research UK (ARUK) consortium who
contributed samples to the ARUK resource. This work was supported by
grants from the US National Institutes of Health, NIA R01 AG18023 (NRG-R,
SGY); Mayo Alzheimer’s Disease Research Center, P50 AG16574 (RCP, DWD,
NRG-R, SGY); Mayo Alzheimer’s Disease Patient Registry, U01 AG06576 (RCP);
and US National Institute on Aging, AG25711, AG17216, AG03949 (DWD).
Samples from the National Cell Repository for Alzheimer’s Disease (NCRAD),
which receives government support under a cooperative agreement grant
(U24AG21886) awarded by the National Institute on Aging (NIA), were used
in this study. This project was also generously supported by the Robert and
Clarice Smith Postdoctoral Fellowship (MMC); Robert and Clarice Smith and
Abigail Van Buren Alzheimer’s Disease Research Program (RCP, DWD, NRG-R,
SGY) and by the Palumbo Professorship in Alzheimer’s Disease Research
(SGY). KM is funded by the Alzheimer’s Research UK and the Big Lottery
Fund. ZKW is partially supported by the NIH/NINDS 1RC2NS070276,
NS057567, P50NS072187, Mayo Clinic Florida (MCF) Research Committee CR
programs (MCF #90052018 and MCF #90052030), Dystonia Medical Research
Foundation, and the gift from Carl Edward Bolch, Jr., and Susan Bass Bolch
(MCF #90052031/PAU #90052). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
The Alzheimer’s Research UK Consortium: Peter Passmore, David Craig,
Janet Johnston, Bernadette McGuinness, Stephen Todd, Queen’s University
Belfast, UK; Reinhard Heun (now at Royal Derby Hospital), Heike Kölsch,
University of Bonn, Germany; Patrick G. Kehoe, University of Bristol, UK; Nigel
M. Hooper, Emma R.L.C. Vardy (now at University of Newcastle), University of
Leeds, UK; David M. Mann, University of Manchester, UK; Kristelle Brown,
Noor Kalsheker, Kevin Morgan, University of Nottingham, UK; A. David Smith,
Gordon Wilcock, Donald Warden, University of Oxford (OPTIMA), UK, Clive
Holmes, University of Southampton, UK.
Author details
1Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville,
FL 32224, USA.
2School of Molecular Medical Sciences, Institute of Genetics,
Queens’s Medical Centre, University of Nottingham, NG7 2UH, UK.
3Biostatistics Unit, Mayo Clinic College of Medicine, Jacksonville, FL 32224,
USA.
4Division of Biomedical Statistics and Informatics, Mayo Clinic College
of Medicine, Rochester, MN 55905, USA.
5Department of Neurology, St.
Olav’s Hospital, Edvard Griegs Gate 8, 7006 Trondheim, Norway.
6Department
of Neuroscience, Norwegian University of Science and Technology, NTNU,
7491 Trondheim, Norway.
7Department of Neurodegenerative Disorders,
Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
8Department of Neurology, Mayo Clinic College of Medicine, Jacksonville, FL
32224, USA.
9Department of Neurology, Mayo Clinic College of Medicine,
Rochester, MN 55905, USA.
10Mayo Alzheimer Disease Research Center, Mayo
Clinic College of Medicine, Rochester, MN 55905, USA.
11Centre for Public
Health, School of Medicine, Dentistry and Biomedical Sciences, Queen’s
University Belfast, Northern Ireland, BT7 1NN, UK.
12OB is now affiliated to
Hospital de la Santa Creu i Sant Pau, 08025, Barcelona, Spain.
Authors’ contributions
Study concept and design: MMC and SGY. Sample Collection and Diagnosis:
ARUK, DWD, JOA, MB, NRG-R, RCP, SBS, and ZKW. Genotyping: MMC and
TAH. DNA Sample Preparation: GDB, ML and ZFG. Analysis and interpretation
of data: JEC, KM, MMC, OB, SGY and VSP. Drafting of the manuscript: MMC
and OB. Critical revision of the manuscript for important intellectual content:
KM, MMC, OB, SGY and VSP. Study supervision: KM, MMC and SGY. All authors
have read and approve the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 26 May 2011 Accepted: 28 July 2011 Published: 28 July 2011
References
1. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-
Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ,
Hulette C, Crain B, Goldgaber D, Roses AD: Association of apolipoprotein E
allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease.
Neurology 1993, 43:1467-1472.
2. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML,
Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C,
Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK,
Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS,
Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD,
Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W,
Jessen F, Schürmann B, van den Bussche H, Heuser I, Kornhuber J,
Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate AM,
Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K,
Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ,
Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE,
Tsolaki M, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S,
Jöckel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS,
Younkin SG, Holmans PA, O’Donovan M, Owen MJ, Williams J: Genome-
wide association study identifies variants at CLU and PICALM associated
with Alzheimer’s disease. Nat Genet 2009, 41:1088-1093.
3. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M,
Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K,
Berr C, Pasquier F, Fiévet N, Barberger-Gateau P, Engelborghs S, De Deyn P,
Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, European Alzheimer’s
Disease Initiative Investigators, de Pancorbo MM, Lendon C, Dufouil C,
Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B,
Bossù P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D,
Licastro F, Soininen H, Ritchie K, Blanché H, Dartigues JF, Tzourio C, Gut I,
Van Broeckhoven C, Alpérovitch A, Lathrop M, Amouyel P: Genome-wide
association study identifies variants at CLU and CR1 associated with
Alzheimer’s disease. Nat Genet 2009, 41:1094-1099.
4. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M,
Bis JC, Smith AV, Carrasquillo MM, Lambert JC, Harold D, Schrijvers EM,
Ramirez-Lorca R, Debette S, Longstreth WT Jr, Janssens AC, Pankratz VS,
Dartigues JF, Hollingworth P, Aspelund T, Hernandez I, Beiser A, Kuller LH,
Koudstaal PJ, Dickson DW, Tzourio C, Abraham R, Antunez C, Du Y, Rotter JI,
Aulchenko YS, Harris TB, Petersen RC, Berr C, Owen MJ, Lopez-Arrieta J,
Varadarajan BN, Becker JT, Rivadeneira F, Nalls MA, Graff-Radford NR,
Campion D, Auerbach S, Rice K, Hofman A, Jonsson PV, Schmidt H,
Lathrop M, Mosley TH, Au R, Psaty BM, Uitterlinden AG, Farrer LA, Lumley T,
Ruiz A, Williams J, Amouyel P, Younkin SG, Wolf PA, Launer LJ, Lopez OL,
van Duijn CM, Breteler MM, CHARGE Consortium, GERAD1 Consortium,
EADI1 Consortium: Genome-wide analysis of genetic loci associated with
Alzheimer disease. JAMA 2010, 303:1832-1840.
Carrasquillo et al. Molecular Neurodegeneration 2011, 6:54
http://www.molecularneurodegeneration.com/content/6/1/54
Page 7 of 95. Carrasquillo MM, Belbin O, Hunter TA, Ma L, Bisceglio GD, Zou F, Crook JE,
Pankratz VS, Dickson DW, Graff-Radford NR, Petersen RC, Morgan K,
Younkin SG: Replication of CLU, CR1, and PICALM associations with
alzheimer disease. Arch Neurol 2010, 67:961-964.
6. Zhang Q, Yu JT, Zhu QX, Zhang W, Wu ZC, Miao D, Tan L: Complement
receptor 1 polymorphisms and risk of late-onset Alzheimer’s disease.
Brain Res 2010, 1348:216-221.
7. Corneveaux JJ, Myers AJ, Allen AN, Pruzin JJ, Ramirez M, Engel A, Nalls MA,
Chen K, Lee W, Chewning K, Villa SE, Meechoovet HB, Gerber JD, Frost D,
Benson HL, O’Reilly S, Chibnik LB, Shulman JM, Singleton AB, Craig DW, Van
Keuren-Jensen KR, Dunckley T, Bennett DA, De Jager PL, Heward C, Hardy J,
Reiman EM, Huentelman MJ: Association of CR1, CLU and PICALM with
Alzheimer’s disease in a cohort of clinically characterized and
neuropathologically verified individuals. Hum Mol Genet 2010,
19:3295-3301.
8. Kamboh MI, Minster RL, Demirci FY, Ganguli M, Dekosky ST, Lopez OL,
Barmada MM: Association of CLU and PICALM variants with Alzheimer’s
disease. Neurobiol Aging , advance online publication: 4 Jun 2010.
9. Yu JT, Li L, Zhu QX, Zhang Q, Zhang W, Wu ZC, Guan J, Tan L: Implication
of CLU gene polymorphisms in Chinese patients with Alzheimer’s
disease. Clin Chim Acta 2010, 411:1516-1519.
10. Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, Buxbaum JD,
Ertekin-Taner N, Fallin MD, Friedland R, Inzelberg R, Kramer P, Rogaeva E, St
George-Hyslop P, Alzheimer’s Disease Genetics Consortium, Cantwell LB,
Dombroski BA, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Lunetta KL,
Martin ER, Montine TJ, Goate AM, Blacker D, Tsuang DW, Beekly D,
Cupples LA, Hakonarson H, Kukull W, Foroud TM, Haines J, Mayeux R,
Farrer LA, Pericak-Vance MA, Schellenberg GD: Meta-analysis Confirms CR1,
CLU, and PICALM as Alzheimer Disease Risk Loci and Reveals
Interactions With APOE Genotypes. Arch Neurol 2010, 67:1473-1484.
11. Yu JT, Song JH, Ma T, Zhang W, Yu NN, Xuan SY, Tan L: Genetic
association of PICALM polymorphisms with Alzheimer’s disease in Han
Chinese. J Neurol Sci 2011, 300:78-80.
12. Schjeide BM, Schnack C, Lambert JC, Lill CM, Kirchheiner J, Tumani H,
Otto M, Tanzi RE, Lehrach H, Amouyel P, von Arnim CA, Bertram L: The role
of clusterin, complement receptor 1, and phosphatidylinositol binding
clathrin assembly protein in Alzheimer disease risk and cerebrospinal
fluid biomarker levels. Arch Gen Psychiatry 2011, 68:207-213.
13. Brouwers N, Van Cauwenberghe C, Engelborghs S, Lambert JC, Bettens K,
Le Bastard N, Pasquier F, Montoya AG, Peeters K, Mattheijssens M,
Vandenberghe R, De Deyn PP, Cruts M, Amouyel P, Sleegers K, Van
Broeckhoven C: Alzheimer risk associated with a copy number variation
in the complement receptor 1 increasing C3b/C4b binding sites. Mol
Psychiatry , advance online publication: 15 March 2011.
14. Lee JH, Cheng R, Barral S, Reitz C, Medrano M, Lantigua R, Jimenez-
Velazquez IZ, Rogaeva E, St George-Hyslop PH, Mayeux R: Identification of
Novel Loci for Alzheimer Disease and Replication of CLU and BIN1 in
Caribbean Hispanic Individuals. Arch Neurol 2011, 68:320-328.
15. Lambert JC, Zelenika D, Hiltunen M, Chouraki V, Combarros O, Bullido MJ,
Tognoni G, Fiévet N, Boland A, Arosio B, Coto E, Del Zompo M, Mateo I,
Frank-Garcia A, Helisalmi S, Porcellini E, Pilotto A, Forti P, Ferri R,
Delepine M, Scarpini E, Siciliano G, Solfrizzi V, Sorbi S, Spalletta G,
Ravaglia G, Valdivieso F, Alvarez V, Bosco P, Mancuso M, Panza F,
Nacmias B, Bossù P, Piccardi P, Annoni G, Seripa D, Galimberti D, Licastro F,
Lathrop M, Soininen H, Amouyel P: Evidence of the association of BIN1
and PICALM with the AD risk in contrasting European populations.
Neurobiol Aging 2011, , 32: 756.e11-756.e15.
16. Wijsman EM, Pankratz ND, Choi Y, Rothstein JH, Faber KM, Cheng R, Lee JH,
Bird TD, Bennett DA, Diaz-Arrastia R, Goate AM, Farlow M, Ghetti B,
Sweet RA, Foroud TM, Mayeux R, NIA-LOAD/NCRAD Family Study Group:
Genome-wide association of familial late-onset Alzheimer’s disease
replicates BIN1 and CLU and nominates CUGBP2 in interaction with
APOE. PLoS Genet 2011, 7:e1001308.
17. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ,
Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-
Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-
Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J,
Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC,
Rogaeva E, St George-Hyslop P, Arnold SE, Barber R, Beach T, Bigio EH,
Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL,
Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C,
DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM,
Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M,
Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B,
Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS,
Hulette CM, Hyman BT, Jicha GA, Jin LW, Johnson N, Karlawish J, Karydas A,
Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP,
Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E,
McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M,
Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC,
Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM,
Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML,
Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ,
Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-
Bohmer KA, Williamson J, Woltjer RL, Cantwell LB, Dombroski BA, Beekly D,
Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA,
Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H,
Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA,
Schellenberg GD: Common variants at MS4A4/MS4A6E, CD2AP, CD33
and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet
2011, 43:436-441.
18. Carrasquillo MM, Belbin O, Hunter TA, Ma L, Bisceglio GD, Zou F, Crook JE,
Pankratz VS, Sando SB, Aasly JO, Barcikowska M, Wszolek ZK, Dickson DW,
Graff-Radford NR, Petersen RC, Morgan K, Younkin SG: Replication of BIN1
Association with Alzheimer’s Disease and Evaluation of Genetic
Interactions. J Alzheimers Dis , advance online publication: 14 Feb 2011.
19. Hu X, Pickering E, Liu YC, Hall S, Fournier H, Katz E, Dechairo B, John S, Van
Eerdewegh P, Soares H: Meta-analysis for genome-wide association study
identifies multiple variants at the BIN1 locus associated with late-onset
Alzheimer’s disease. PloS one 2011, 6:e16616.
20. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM,
Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N,
Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J,
Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC,
Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B,
Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G,
Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC,
Rossor M, Collinge J, Maier W, Jessen F, Rüther E, Schürmann B, Heun R,
Kölsch H, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M,
Frölich L, Hampel H, Gallacher J, Hüll M, Rujescu D, Giegling I, Goate AM,
Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K,
Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ,
Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE,
Tsolaki M, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S,
Jöckel KH, Klopp N, Wichmann HE, Pankratz VS, Sando SB, Aasly JO,
Barcikowska M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC,
Alzheimer’s Disease Neuroimaging Initiative, van Duijn CM, Breteler MM,
Ikram MA, DeStefano AL, Fitzpatrick AL, Lopez O, Launer LJ, Seshadri S,
CHARGE consortium, Berr C, Campion D, Epelbaum J, Dartigues JF,
Tzourio C, Alpérovitch A, Lathrop M, EADI1 consortium, Feulner TM,
Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S,
Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, Snaedal J,
Björnsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M,
Soininen H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F,
Mateo I, Frank-Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P,
Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, Sorbi S, Bossù P,
Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A, Scarpini E, Galimberti D,
Brice A, Hannequin D, Licastro F, Jones L, Holmans PA, Jonsson T,
Riemenschneider M, Morgan K, Younkin SG, Owen MJ, O’Donovan M,
Amouyel P, Williams J: Common variants at ABCA7, MS4A6A/MS4A4E,
EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat
Genet 2011, 43:429-435.
21. Belbin O, Carrasquillo MM, Crump M, Culley OJ, Hunter TA, Ma L,
Bisceglio G, Zou F, Allen M, Dickson DW, Graff-Radford NR, Petersen RC,
Morgan K, Younkin SG: Investigation of 15 of the top candidate genes for
late-onset Alzheimer’s disease. Hum Genet 2011, 129:273-282.
22. Sando SB, Melquist S, Cannon A, Hutton ML, Sletvold O, Saltvedt I,
White LR, Lydersen S, Aasly JO: APOE epsilon 4 lowers age at onset and is
a high risk factor for Alzheimer’s disease; a case control study from
central Norway. BMC Neurol 2008, 8:9.
23. Klimkowicz-Mrowiec A, Marona M, Wolkow P, Maruszak A, Styczynska M,
Barcikowska M, Zekanowski C, Szczudlik A, Slowik A: Interleukin-1 gene
Carrasquillo et al. Molecular Neurodegeneration 2011, 6:54
http://www.molecularneurodegeneration.com/content/6/1/54
Page 8 of 9-511 CT polymorphism and the risk of Alzheimer’s disease in a Polish
population. Dement Geriatr Cogn Disord 2009, 28:461-464.
24. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials
1986, 7:177-188.
25. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J,
Sklar P, de Bakker PI, Daly MJ, Sham PC: PLINK: a tool set for whole-
genome association and population-based linkage analyses. Am J Hum
Genet 2007, 81:559-575.
doi:10.1186/1750-1326-6-54
Cite this article as: Carrasquillo et al.: Replication of EPHA1 and CD33
associations with late-onset Alzheimer’s disease: a multi-centre case-
control study. Molecular Neurodegeneration 2011 6:54.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Carrasquillo et al. Molecular Neurodegeneration 2011, 6:54
http://www.molecularneurodegeneration.com/content/6/1/54
Page 9 of 9